Adare Pharmaceuticals has entered into an agreement with Egalet Corporation to acquire global rights of the Parvulet technology platform and its associated intellectual property (IP). The technology is protected by several patents granted in the U.S., Canada and Europe with patent life ranging from five to 10 years.
 
Using commonly used pharmaceutical excipients, the technology enables single-dose formulation of taste-masked, easy-to-swallow oral medications with a soft food like texture for pediatric and geriatric populations—including those with dysphagia. One of the unique features of the technology is its ability to enable high dose regimens that may not be feasible by other means, according to the company. Parvulet technology will be complementary to the existing proprietary technologies owned by Adare Pharmaceuticals, allowing the company to expand its product development capabilities.
 
“We are excited to bring this new technology into our portfolio of proven product development technology platforms,” said Ajay Damani, vice president, pharmaceutical technologies, Adare. “It demonstrates our commitment to advancing novel technologies for improved drug delivery mechanisms and better healthcare solutions for patients.”
 
Under the agreement, Egalet will transfer the IP and know-how to Adare Pharmaceuticals, effective immediately. Details of the agreement terms were not disclosed.
 
“Given our focus on our seven commercial products, we are pleased to have signed this agreement enabling Adare to leverage the Parvulet technology to develop new products,” said Mark Strobeck, chief operating officer, Egalet.